State Street’s NeuroOne Medical Technologies NMTC Stock Holding History

State Street’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,917	Closed	-$46.2K	–	4242
2026 Q1	$46.2K	Hold	9,917	–	–	﹤0.01%	4141
2025 Q4	$45.1K	Hold	9,917	–	–	﹤0.01%	4170
2025 Q3	$52.9K	Hold	9,917	–	–	﹤0.01%	4149
2025 Q2	$40.4K	Hold	9,917	–	–	﹤0.01%	4123
2025 Q1	$50.6K	Hold	9,917	–	–	﹤0.01%	4095
2024 Q4	$49.1K	Hold	9,917	–	–	﹤0.01%	4110
2024 Q3	$58.9K	Hold	9,917	–	–	﹤0.01%	4072
2024 Q2	$47.6K	Buy	9,917 +1,317	+15%	+$8.28K	﹤0.01%	4149
2024 Q1	$61.9K	Hold	8,600	–	–	﹤0.01%	4123
2023 Q4	$81.5K	Hold	8,600	–	–	﹤0.01%	4094
2023 Q3	$45.9K	Buy	8,600 +2,617	+44%	+$17.5K	﹤0.01%	4304
2023 Q2	$43.1K	Hold	5,983	–	–	﹤0.01%	4457
2023 Q1	$57.8K	Hold	5,983	–	–	﹤0.01%	4469
2022 Q4	$43.1K	Hold	5,983	–	–	﹤0.01%	4589
2022 Q3	$61K	Buy	+5,983	New	+$56.9K	﹤0.01%	4613

Other funds holding NMTC

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

State Street's NMTC Position: Q2 2026 in Review

State Street sold out of NeuroOne Medical Technologies (NMTC) in Q2 2026, closing a stake of 9,917 shares — an estimated $46.2K sold.

State Street first reported a position in NMTC in Q3 2022 and held it in 15 quarters. The position peaked at $81.5K in Q4 2023. 27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

State Street reported no remaining NeuroOne Medical Technologies position as of Q2 2026 after selling out during the quarter.
State Street sold 9,917 NeuroOne Medical Technologies shares in Q2 2026, an estimated $46.2K.
State Street first reported a position in NeuroOne Medical Technologies in Q3 2022 and held it in 15 quarters.
State Street's NeuroOne Medical Technologies position peaked at $81.5K in Q4 2023.
27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.